Oakwood Labs is happy to announce that we will be exhibiting at Booth #748 at the upcoming 2025 Convention on Pharmaceutical Ingredients (CPHI) on May 20-22 in Philadelphia, Pennsylvania. If you would like to learn more about the event and register to attend, please visit the following link: https://www.cphi.com/americas/en/home.html

Company Overview

Oakwood Labs is a global leader in sustained release drug delivery. We support all phases of long acting injectable development from initial feasibility studies through FDA-approved clinical and commercial supply. Oakwood has 28 years of drug encapsulation experience using Chroniject™, our patented microsphere-based technology. Chroniject™ provides the ability to control particle size, customize release durations from weeks to years, and minimize residual solvents to achieve critical quality attributes.

Stop by Oakwood Lab’s Booth #748 to meet our team and learn more about how we can assist in the following areas:

• Long Acting Injectable Technology (CDMO)
• Feasibility studies
• Scale-up and optimization of formulation
• Manufacturing GLP toxicology batches
• Clinical trial manufacturing (Phase I, II, III)
• Contract Manufacturing (CMO)
• Technology Transfer
• GMP Registration and Validation batches
• Aseptic GMP commercial batch manufacturing
• ICH compliant stability testing

Contact Us for More Information

The CPHI Americas 2025 conference covers a wide range of topics, and we are happy to contribute to the event! If you aren’t able to attend, but still want to learn more about Oakwood Labs or what you missed at the conference, contact us today!

We look forward to discussing our technology and more.